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Abstract
RNA-binding proteins of the Musashi (Msi) family are expressed in stem cell compartments and
in aggressive tumors, but they have not yet been widely explored in the blood. Here we
demonstrate that Msi2 is the predominant form expressed in hematopoietic stem cells (HSCs), and
its knockdown leads to reduced engraftment and depletion of HSCs in vivo. Overexpression of
human MSI2 in a mouse model increases HSC cell cycle progression and cooperates with the
chronic myeloid leukemia–associated BCR-ABL1 oncoprotein to induce an aggressive leukemia.
MSI2 is overexpressed in human myeloid leukemia cell lines, and its depletion leads to decreased
proliferation and increased apoptosis. Expression levels in human myeloid leukemia directly
correlate with decreased survival in patients with the disease, thereby defining MSI2 expression as
a new prognostic marker and as a new target for therapy in acute myeloid leukemia (AML).
Musashi family RNA-binding proteins have been linked to tissue stem cells but not yet
studied extensively in the blood1,2. Deregulation of key genes that control self-renewal and
cell fate decisions in HSCs can contribute to the onset and progression of leukemia3. To
identify previously unknown regulators of HSC function and leukemogenesis, we performed
gene expression profiling of sorted mouse hematopoietic stem and progenitor cells (defined
as LinlowSca1+c-Kit+; LSK cells) and committed progenitor cells (LinlowSca1−c-Kit+; LK
cells) and analyzed genes that were differentially expressed in these populations. Numerous
genes implicated in leukemia were preferentially expressed in hematopoietic stem and
progenitor cells, including those encoding the transcription factors ecotropic viral integration
site-1 (Mecom, also known as Evi1), pre-B-cell leukemia homeobox 1 (Pbx1) and members
of the homeobox A cluster (Hoxa) (Supplementary Fig. 1a). Notably, the gene encoding the
Msi2 RNA-binding protein, which has been found to be fused with the HOXA9 locus as a
result of chromosomal translocations in two individuals with blast crisis chronic
myelogenous leukemia (CML-BC)4,5, was expressed fivefold higher in hematopoietic stem
and progenitor cells relative to committed progenitor cells (Supplementary Fig. 1a). Msi2
expression is upregulated in leukemic progenitors transduced with Vp16/Meis1, a fusion of
the Vp16 activation domain to the transcription factor Meis1, indicating that Msi2 might be
a key gene for self-renewal in leukemia6.
The Msi proteins affect asymmetric cell division, germ and somatic stem cell function and
cell fate determination in various somatic tissues7. The Msi gene family is evolutionarily
conserved and encodes two closely related proteins, Msi1 and Msi2. Msi1 binds consensus
motifs in the 3′untranslated regions of mRNAs, interacts with the poly(A)–binding protein
and competes for eukaryotic initiation factor-4G, thereby interfering with translation
initiation8. Msi1 can target developmental transcription factors and cell cycle regulators.
Specifically, Msi1 directly binds and suppresses mRNA translation of Numb, a negative
regulator of Notch signaling, which influences neural development9. Through an indirect
mechanism, Msi1 increases growth factor signaling, leading to enhanced phosphorylation of
extracellular signal-regulated kinase (Erk) in mammary epithelial progenitors2. Thus, Msi1
directly and indirectly affects multiple targets that influence both cell proliferation and cell
fate decisions. The function and targets of Msi2 have not been characterized as extensively
as for Msi1, although there is evidence supporting their functional redundancy in neural
progenitor cells1.
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RESULTS
MSI2 is expressed in HSCs
To understand the role of Msi2 in hematopoiesis, we characterized its expression by
quantitative RT-PCR in fractionated cell populations from mouse bone marrow and spleen.
We observed higher expression of Msi2 in populations enriched for hematopoietic stem cells
compared to progenitor cells, differentiated myeloid cells and lymphocytes, confirming our
microarray results (Fig. 1a)10. Msi1 mRNA was nearly undetectable by microarray and
quantitative RT-PCR (Supplementary Fig. 1b,c). To test the role of Msi2 expression in
hematopoiesis, we knocked down Msi2 with short hairpin RNA and confirmed its reduced
expression in a leukemic cell line (Supplementary Fig. 1d). We then sorted, transduced and
transplanted enriched hematopoietic stem and progenitor cell populations with shRNA
vectors that co-expressed enhanced GFP (EGFP; Fig. 1b) into wild-type C57BL/6 mice. Six
weeks after transplantation, we observed a reduced percentage of total EGFP+ cells in the
peripheral blood and in long-term HSCs of the bone marrow relative to input populations
and to mice engrafted with control shRNA–infected cells (Fig. 1c–d). Although we did not
specifically assess homing of the HSCs, the reduced contribution of Msi-2–depleted cells
was not likely due to a general defect in homing of hematopoietic cells to the bone marrow
(Supplementary Fig. 1e). The loss of engraftment of Msi2-depleted HSCs indicates that
Msi2 has a major role in HSC function after marrow transplantation.
To examine how increased MSI2 expression might alter stem cell dynamics and to model
human leukemia, we developed a transgenic mouse strain in which expression of human
MSI2 is doxycycline inducible (Supplementary Figs. 2 and 3a)11,12. We verified dose-
dependent, doxycycline-inducible expression of MSI2 both in vitro (Supplementary Fig. 3b)
and in vivo (Supplementary Fig. 3c,d). We initially examined how MSI2 could alter
hematopoietic progenitor cell function by performing in vitro colony-forming unit (CFU)
assays with mouse bone marrow cells. When MSI2 expression was induced, we observed a
significant decrease in multipotent granulocyte-erythroid-monocyte-megakaryocyte (CFU-
GEMM) and megakaryocyte (CFU-MEG) colonies (P < 0.05) but no differences in
granulocytic, monocytic or mixed granulocytic-monocytic colonies (Supplementary Fig. 3e).
Moreover, we detected no change in the serial replating potential of progenitors
(Supplementary Fig. 3f), suggesting that ectopic MSI2 expression did not provoke aberrant
self-renewal. Flow cytometry of hematopoietic colonies formed in vitro showed decreased
Gr1 and increased c-Kit staining, indicating a more immature myeloid phenotype, which
was confirmed by inspection of cell morphology (Supplementary Fig. 3g,h). Myeloid cells
formed in the presence of interleukin-3 or granulocyte-macrophage colony–stimulating
factor alone were similarly immature (Supplementary Fig. 3i–k). Taken together, these in
vitro data indicate that overexpression of MSI2 inhibits differentiation of early myeloid,
megakaryocytic and granulocytic lineages.
MSI2 overexpression alters HSC function
To examine how increased MSI2 influences stem and progenitor cell function in vivo, we
examined recipient mice that were reconstituted with bone marrow from control mice
harboring a reverse tetracycline transactivator only (rtTA) or MSI2-transgenic mice. Six
weeks after transplantation, we induced MSI2 overexpression with 5 d of doxycy-cline
treatment and measured the acute effects in the stem and myeloid progenitor cell
compartments of the bone marrow. We observed a significant increase in hematopoietic
stem and progenitor cells (LSK cells) within bone marrow of MSI2-induced mice, in terms
of both percentage (Fig. 2a and Supplementary Fig. 4a) and absolute cell numbers
(Supplementary Fig. 4b). This coincided with a decrease in the percentage and number of
the common myeloid progenitor and myeloid erythroid progenitor cells (Supplementary Fig.
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4b,c). In the transplant recipients, MSI2 induction also increased the number of long-term
HSCs (defined as SLAM: LSK and CD150+CD48−, or LSK and CD34−; Fig. 2b)10. We
observed comparable effects in primary (nontransplanted) MSI2-inducible mice
administered doxycycline for 5 d (Supplementary Fig. 5a,b). The quantitative expansion of
total hematopoietic stem and progenitor (LSK) cells was accompanied by a decrease in the
percentage of long-term HSCs, indicating a preferential expansion of the short-term HSC
(Fig. 2a and Supplementary Fig. 4d). Consistent with this, the increase in HSC numbers was
associated with a reduction in quiescent (G0) cell numbers and a concomitant increase in the
percentage of G1 and cycling cells (S-G2-M) in both hematopoietic stem and progenitor
cells and in long-term HSCs (Fig. 2c and Supplementary Fig. 4e). To further define the
effects of MSI2 on stem cell proliferation, we sorted SLAM cells and multipotential
progenitors (MPPs), (LSK, CD150−CD48−) and found that ectopic MSI2 expression
increased the proliferation of MPPs but not long-term HSCs (Supplementary Fig. 4f). The
observed expansion of MPPs is consistent with our previous in vivo results suggesting an
expansion of the LSKs (Fig. 2a). The long-term HSCs and MPPs were not undergoing
increased apoptosis in response to ectopic MSI2 activity (Supplementary Fig. 4g). We found
an increase in the frequency of cobblestone area–forming cells, reflecting primitive
hematopoietic progenitors, in MSI2-induced cells compared to control cells (Supplementary
Fig. 4h), providing further evidence that MSI2 expression can lead to short-term progenitor
cell expansion.
We performed transcriptome profiling in hematopoietic stem and progenitor cells to identify
pathways activated by MSI2 expression using gene set enrichment analysis13. We found
increased expression of RAS mitogen-activated protein kinase (Mapk)-, cyclin D1- and
Myc-induced gene expression signatures in response to MSI2 induction (Fig. 2d and
Supplementary Table 1). These data, in conjunction with a previous study indicating that
Msi1 can alter Mapk signaling in mammary progenitors2, prompted us to stimulate
hematopoietic stem and progenitor cells with stem cell factor (SCF), after which we
observed enhanced phospho-Erk levels (Fig. 2e). The increased Erk signaling coincides with
expansion of the HSCs. Asymmetric partitioning of Numb protein in HSCs that have
recently undergone cell division is known to mark the more committed (Numb-positive) of
the two daughter cells14. Because Numb is a known Msi1 target, we examined how MSI2
induction alters Numb localization during cell division14. The percentage of cells
undergoing asymmetric Numb segregation increased in MSI2-expressing hematopoietic
stem and progenitor cells (Fig. 2f), indicating commitment toward progenitor fate.
To further test the impact of MSI2 on stem cell function and maintenance of the
hematopoietic system in vivo, we performed both whole-marrow and mixed competitive
transplants with bone marrow from control rtTA and mice in which the MSI2 gene is
doxycycline inducible. In initial experiments, we administered doxycycline starting 4 weeks
after engraftment. Mice analyzed at 6 and 16 weeks showed reduced numbers of neutrophils,
lymphocytes and platelets and increases in hematocrit and mean corpuscular volume (Fig.
2g and Supplementary Fig. 6a–f). In competitive transplants, MSI2-inducible or control rtTA
bone marrow (CD45.2+) was mixed with CD45.1+ congenic competitor cells in either 1:1 or
3:1 ratios. As in the noncompetitive transplant setting, we observed a reduced contribution
from MSI2-expressing cells in peripheral blood, with a 50% decrease in hematopoietic
chimerism at both ratios (Fig. 2h). We observed this relative deficiency of MSI2-expressing
CD45.2+ cells in myeloid, B and T lineages and at time points corresponding to
reconstitution from both short-term and long-term HSCs (6 and 20 weeks, respectively;
Supplementary Fig. 7a–d). A reduced contribution from MSI2-expressing cells was likewise
directly analyzed in the long-term HSC and progenitor cell compartments 20 weeks after
transplantation (Fig. 2i and Supplementary Fig. 8). Together, these data indicate that ectopic
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MSI2 expression drives proliferation of long-term HSCs toward progenitors, resulting in
reduced stem cell pools.
MSI2 cooperates with BCR-ABL1 during leukemogenesis
Several recent reports have linked MSI family members to the pathogenesis of solid tumors.
Expression of MSI1 is increased in pediatric brain tumors, and knockdown of MSI1 in the
HCT116 colon adenocarcinoma cell line reduces tumor burden in vivo5,15. Mice
transplanted with doxycycline-inducible MSI2 bone marrow and followed for 1 year with
continuous doxycycline treatment did not develop leukemia, although spleen and liver
weights were modestly increased (Supplementary Fig. 9a,b). Notably, however, we observed
only minimal MSI2 overexpression in these mice after 1 year of doxycycline treatment,
indicating that selection against cells expressing high amounts of MSI2 occurs over time
(Supplementary Fig. 9c). To test whether MSI2 overexpression might transform
immortalized cell lines in culture, we transduced the mouse interleukin-3–dependent pro-B
cell line Ba/F3 with an MSI2-expressing retrovirus (Fig. 3a). We observed cytokine-
independent growth, consistent with hematopoietic transformation (Fig. 3b). Thus, we
hypothesized that MSI2 might potentiate transformation in hematopoietic cells in
cooperation with other genetic lesions. To test whether MSI2 could cooperate with the
CML-specific oncogene BCR-ABL1 to induce disease progression, we transduced
doxycycline-inducible MSI2 bone marrow cells with BCR-ABL1 and assessed leukemia
development after bone marrow transplantation. Doxycycline treatment was initiated 3 d
after transplantation, and mice were killed within 14 d owing to a rapid and lethal
myeloproliferative disease. When compared to transformation with BCR-ABL1 alone,
concurrent expression of MSI2 resulted in increased tumor burden in the peripheral blood,
bone marrow and spleen (Fig. 3c–f and Supplementary Fig. 10a,b), and flow cytometry of
splenic cells revealed a shift toward a more immature myeloid phenotype (signified by the
markers Mac1highGr1low; Fig. 3g and Supplementary Fig. 10c). Consistent with the
observed increase in the immature Mac1highGr1low population, inspection of peripheral
blood smears (Supplementary Fig. 10d) and analysis of bone marrow and spleen histology
(Fig. 3h) showed increased numbers of leukemic blasts and infiltration with immature
myeloid cells. In this mouse model, the leukemia-initiating cells (LICs) are defined as BCR-
ABL1+Lin−c-Kit+Sca+ (ref. 16). However, despite the increased tumor burden in the mice
subjected to transformation by both BCR-ABL1 and MSI2, we detected no difference in the
number or frequency of phenotypic LICs (Supplementary Fig. 10e,f). Although not affecting
the numbers of LICs, MSI2 seems to functionally alter the LIC compartment when
expressed with BCR-ABL1, as MSI2 induces a more immature myeloid leukemia that
resembles the accelerated or blastic phases of human CML.
Given that MSI2 can act as a cooperating oncogene in our mouse model, we examined MSI2
expression in human leukemia and found MSI2 over-expression in cell lines from
individuals with AML and CML-BC (Fig. 4a and Supplementary Fig. 11a). Knockdown
experiments have implicated a functional role for MSI1 in several cancers17–19. To test the
functional role of increased MSI2 expression in leukemic cells, we transduced several cell
lines with lentiviral shRNA vectors targeting MSI2 (Supplementary Fig. 11b,c). Knockdown
of MSI2 led to a decrease in proliferation in the AML cell lines NOMO-1 and THP-1 and the
CML-BC cell lines AR230 and LAMA-84, and all four leukemic cell lines showed a marked
induction of apoptosis, as assessed by annexin V staining (Fig. 4b,c and Supplementary Fig.
11b–d). Five days after MSI2 knockdown, LAMA-84 cells became more differentiated, as
evidenced by increased expression of CD11b and CD16 (Fig. 4d and Supplementary Fig.
11d). We also observed increased NUMB protein amounts upon MSI2 knockdown,
consistent with the reported role of MSI1 in suppressing NUMB mRNA translation
(Supplementary Fig. 11c)9.
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To better understand the role of MSI2 in human leukemias, we assessed the gene expression
profiles of the four human leukemia cell lines 72 h after MSI2 knockdown. As expected,
MSI2 was the most downregulated gene (Supplementary Fig. 12a). Gene signatures that
were significantly altered upon MSI2 knockdown include decreased expression of target
genes downstream of each of the following pathways: Wnt, Ras-Mapk and Myc
(Supplementary Fig. 12b–e and Supplementary Table 1)20–22. Notably, we found these
pathways to be upregulated in mouse hematopoietic stem cells and progenitor cells
overexpressing MSI2 (Fig. 2d and Supplementary Table 1). Additionally, we noted that a
differentiation signature comprised of genes with higher expression in granulocyte
monocyte progenitors compared to HSCs23 correlated positively with the gene expression
profile of MSI2-knockdown leukemic cells (Supplementary Fig. 12f). Collectively, these
data demonstrate that decreased MSI2 expression is associated with decreased expression of
proliferation and survival genes, along with elevated expression of markers of myeloid
differentiation.
Increased MSI2 expression associates with worse clinical prognosis
To determine whether aberrant MSI2 expression might also have a role in primary human
leukemia, we examined MSI2 expression in a previously published gene expression data set
obtained from individuals with CML24. Our examination of these data showed increased
levels of MSI2 in CML-BC relative to chronic-phase CML (Fig. 4e). We found NUMB
expression levels significantly lower than those of MSI2, in both chronic phase and blast
crisis (P < 0.001) (Supplementary Fig. 12g). Increased Numb expression and reduced
disease burden was previously observed in a study in which the hedgehog pathway was
ablated in mouse BCR-ABL1–transduced HSCs25. Taken together, our data implicate
increased levels of MSI2 in AML and CML-BC and establish an inverse correlation with
NUMB expression.
We also examined MSI2 expression data derived from 436 individuals with AML.
Expression of MSI2 was markedly associated with specific cytogenetic and molecular
genetic aberrations. For example, subjects with AML with inversion of chromosome 16
showed lower MSI2 levels relative to other leukemia subgroups (P <0.05; Supplementary
Fig. 13a), whereas MSI2 expression was higher in individuals harboring monosomy 7 (P <
0.001; Supplementary Fig. 13a). Furthermore, elevated MSI2 expression was associated with
fms-related tyrosine kinase-3 (FLT3) internal tandem duplications and nucleophosmin-1
(NPM1) mutations but not with mixed-lineage-leukemia 1 partial tandem duplication (MLL-
PTD) and CCAAT/enhancer binding protein alpha (CEBPa) (Supplementary Fig. 13b–e)26.
More notably, subjects with AML with MSI2 mRNA expression above the median were
characterized by worse clinical outcome (median overall survival, 405 d versus 845 d; P <
0.001, Fig. 4f and Supplementary Fig. 13f)26. This effect of MSI2 on prognosis was not due
to its association with cytogenetic subgroups, as excluding the good-prognosis group
harboring the inversion of chromosome 16 still yielded a significant result on prognosis (P <
0.01) (Supplementary Fig. 13g). In contrast to MSI2, MSI1 was not expressed in subjects
with CML or AML or in the leukemic cell lines (Supplementary Fig. 14a–c and data not
shown). Ultimately, multivariate Cox proportional-hazard regression analysis demonstrated
that MSI2 is an independent prognostic marker in AML when considering age, French-
American-British classification of leukemia pathology, cytogenetics and the mutation status
of FLT3 and NPM1 (Supplementary Tables 2 and 3).
We confirmed the association between MSI2 expression and poor clinical prognosis in an
independent cohort of subjects with AML with normal karyotype (Fig. 4g and
Supplementary Table 4)27. In this data set, gene expression signatures from people with
cytogenetically normal AML (CN-AML) and a poor clinical outcome positively correlated
with gene expression signatures of people in the MSI2-high subset and negatively correlated
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with genes altered by MSI2 knockdown (Supplementary Fig. 15a and Supplementary Table
1)27. We selected the genes from the MSI2-knockdown expression signature and performed
an unsupervised clustering of the AML samples; this defined two main clusters (Fig. 4h and
Supplementary Table 5). The positive cluster correlated with the MSI2-knockdown signature
in individuals with improved survival, whereas the negative cluster was associated with poor
prognosis (Fig. 4i). Additionally, oncogenic and HSC gene expression signatures were
positively correlated with those of individuals in the CN-AML high-MSI2-expression data
set (Supplementary Fig. 15b and Supplementary Table 4).
DISCUSSION
In summary, we have shown by overexpression and knockdown strategies in both mouse
and human systems that the mRNA-binding protein MSI2 influences proliferation and
differentiation of HSCs and myeloid progenitors. Moreover, we have observed that
dysregulated MSI2 expression is associated with aggressive myeloid leukemia, thereby
implicating MSI2 as a previously unknown regulator of both normal and malignant
hematopoiesis (Supplementary Fig. 16a,b). Several factors that regulate hematopoietic
differentiation and progenitor cell fate determination, such as the transcription factors
IKAROS and CCAAT/enhancer binding protein (CEBP) family members as well as
microRNAs in the Let7 family, have been implicated in leukemogenesis by arresting
differentiation and promoting self-renewal3,28,29. The MSI2 RNA-binding protein may act
similarly to these factors by regulating HSC proliferation and maintaining an
undifferentiated gene expression program in leukemia, contributing to poor clinical
outcome. Targeting MSI2 may ultimately allow selective suppression of leukemic stem cell
populations and provide a new therapeutic strategy in leukemia.
METHODS
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/nm/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We would like to thank S. Armstrong (Children’s Hospital Boston) for valuable reagents. We would like to
acknowledge T. Zhang, D. Kalaitzidis, K. Gritsman, P. Stern and S. Sykes for their critical suggestions and J.-A.
Kwon for assistance with microarray processing. We would like to thank M. Wernig for his assistance with the
project. M.G.K. was supported by the US National Institutes of Health (NIH) National Institute of Diabetes and
Digestive and Kidney Diseases Career Development Award. This work was supported by grants from the NIH
(D.G.G., R.J. and G.Q.D.), the Leukemia and Lymphoma Society (D.G.G. and G.Q.D.) and the Howard Hughes
Medical Institute (D.G.G. and G.Q.D.). C.J.L. was supported by a Ruth L. Kirschstein Fellowship from the NIH.
References
1. Sakakibara S, et al. RNA-binding protein Musashi family: roles for CNS stem cells and a
subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc Natl
Acad Sci USA. 2002; 99:15194–15199. [PubMed: 12407178]
2. Wang XY, et al. Musashi1 modulates mammary progenitor cell expansion through proliferin-
mediated activation of the Wnt and Notch pathways. Mol Cell Biol. 2008; 28:3589–3599. [PubMed:
18362162]
3. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer.
2003; 3:89–101. [PubMed: 12563308]
Kharas et al. Page 7
Nat Med. Author manuscript; available in PMC 2011 May 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4. Barbouti A, et al. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently
rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with
HOXA9 as a result of the cryptic t(7;17)(p15;q23). Cancer Res. 2003; 63:1202–1206. [PubMed:
12649177]
5. Hemmati HD, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci
USA. 2003; 100:15178–15183. [PubMed: 14645703]
6. Wang GG, Pasillas MP, Kamps MP. Persistent transactivation by meis1 replaces hox function in
myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes
on promoters of leukemia-associated genes. Mol Cell Biol. 2006; 26:3902–3916. [PubMed:
16648484]
7. Okano H, et al. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res. 2005;
306:349–356. [PubMed: 15925591]
8. Kawahara H, et al. Neural RNA-binding protein Musashi1 inhibits translation initiation by
competing with eIF4G for PABP. J Cell Biol. 2008; 181:639–653. [PubMed: 18490513]
9. Imai T, et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb
gene expression by interacting with its mRNA. Mol Cell Biol. 2001; 21:3888–3900. [PubMed:
11359897]
10. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish
hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;
121:1109–1121. [PubMed: 15989959]
11. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-
cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005; 121:465–477. [PubMed:
15882627]
12. Beard C, Hochedlinger K, Plath K, Wutz A, Jaenisch R. Efficient method to generate single-copy
transgenic mice by site-specific integration in embryonic stem cells. Genesis. 2006; 44:23–28.
[PubMed: 16400644]
13. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102:15545–15550. [PubMed:
16199517]
14. Wu M, et al. Imaging hematopoietic precursor division in real time. Cell Stem Cell. 2007; 1:541–
554. [PubMed: 18345353]
15. Sureban SM, et al. Knockdown of RNA binding protein musashi-1 leads to tumor regression in
vivo. Gastroenterology. 2008; 134:1448–1458. [PubMed: 18471519]
16. Huntly BJ, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to
committed murine hematopoietic progenitors. Cancer Cell. 2004; 6:587–596. [PubMed:
15607963]
17. Kanai R, et al. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant
expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of
malignant glioma. Hum Gene Ther. 2007; 18:63–73. [PubMed: 17238803]
18. Nikpour P, et al. The RNA binding protein Musashi1 regulates apoptosis, gene expression and
stress granule formation in urothelial carcinoma cells. J Cell Mol Med. May 14.2010 published
online. 10.1111/j.1582-4934.2010.01090.x
19. Kanai R, et al. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-
small cell lung cancer–expression of an RNA-binding protein, Musashi1, as a marker for the
tailored gene therapy. J Gene Med. 2006; 8:1329–1340. [PubMed: 16955534]
20. Creighton CJ. Multiple oncogenic pathway signatures show coordinate expression patterns in
human prostate tumors. PLoS One. 2008; 3:e1816. [PubMed: 18350153]
21. Bild AH, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Nature. 2006; 439:353–357. [PubMed: 16273092]
22. Guo J, Jin J, Cooper LF. Dissection of sets of genes that control the character of wnt5a-deficient
mouse calvarial cells. Bone. 2008; 43:961–971. [PubMed: 18656562]
23. Krivtsov AV, et al. Transformation from committed progenitor to leukaemia stem cell initiated by
MLL-AF9. Nature. 2006; 442:818–822. [PubMed: 16862118]
Kharas et al. Page 8
Nat Med. Author manuscript; available in PMC 2011 May 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
24. Radich JP, et al. Gene expression changes associated with progression and response in chronic
myeloid leukemia. Proc Natl Acad Sci USA. 2006; 103:2794–2799. [PubMed: 16477019]
25. Zhao C, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid
leukaemia. Nature. 2009; 458:776–779. [PubMed: 19169242]
26. Bullinger L, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute
myeloid leukemia. N Engl J Med. 2004; 350:1605–1616. [PubMed: 15084693]
27. Metzeler KH, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically
normal acute myeloid leukemia. Blood. 2008; 112:4193–4201. [PubMed: 18716133]
28. Mullighan CG, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of
Ikaros. Nature. 2008; 453:110–114. [PubMed: 18408710]
29. Viswanathan SR, et al. Lin28 promotes transformation and is associated with advanced human
malignancies. Nat Genet. 2009; 41:843–848. [PubMed: 19483683]
30. Kang H, et al. Gene expression classifiers for relapse-free survival and minimal residual disease
improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic
leukemia. Blood. 2009; 115:1394–1405. [PubMed: 19880498]
Kharas et al. Page 9
Nat Med. Author manuscript; available in PMC 2011 May 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Msi2 is expressed in HSCs, and its depletion reduces engraftment in vivo. (a) Quantitative
RT-PCR of Msi2 expression in purified hematopoietic populations. SLAM, CMP, common
myeloid progenitor; GMP, granulocyte monocyte progenitor; MEP, myeloerythroid
progenitor; B, T, lymphocytes. Error bars represent s.e.m. for at least four experiments. (b)
Strategy for Msi2 shRNA knockdown in vivo. Viral vectors carrying control scrambled
shRNA (Csh) or shRNAs targeting Msi2 (Msh) along with EGFP were transduced into LSK
cells followed by transplant into lethally irradiated mice (red bolts). (c) Relative engraftment
of whole peripheral blood (PB) and purified bone marrow stem and progenitor cell
populations (LSK, Linlow Sca+ c-Kit+; long-term HSC, LSK CD34+; LK, LinlowSca−c-Kit+)
by cells infected with shRNA (Msh or Csh at 6 weeks after transplant. The ratio of EGFP+
cells in the indicated populations is relative to input (representative of three independent
transplants and at least eight mice; NS, not significant, +P < 0.05, *P < 0.01, statistical
nomenclature used throughout subsequent figures). (d) Representative flow cytometric
analysis of bone marrow stem and progenitor cells from engrafted mice at 6 weeks after
transplant.
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Figure 2.
Ectopic MSI2 expression compromises HSC function. Bone marrow from control rtTA (C)
or MSI2-transgenic (M) mice was transplanted into irradiated CD45.1+ congenic mice. Six
weeks after transplantation, doxycycline was given for 5 d, and bone marrow was analyzed
for HSC and progenitor cells. (a) Representative flow cytometric plots, with percentages of
cells expressing markers as indicated. The analyzed populations are indicated above the
plots. (b) Quantification of long-term HSCs (SLAM: LSK CD150+CD48+ or LSK CD34−).
(c) Cell cycle analysis performed with Hoechst and pyronin Y, gated on hematopoietic stem
and progenitor cells (LSK cells) (representative experiment from at least seven mice; error
bars, s.e.m.). (d) Gene set enrichment analysis (GSEA) on microarray data of MSI2-
overexpressing LSKs (Supplementary Methods). (e) Determination of ERK phosphorylation
in LSKs after stimulation with SCF. Representative plot shown; histogram indicates
combined analysis of five mice from two independent experiments. (f) Determination of
symmetric versus asymmetric cell divisions in purified LSKs. Immunofluorescence images
stained for Numb (left) and DAPI (right) and bright field (middle). Scale bars, 10 μm. A
quantification is presented as pie charts below the images (C, n = 4 experiments, 70%
symmetric ± 9.2% (n = 58 cells) and M, n = 5 experiments, 33% symmetric ± 13.2% (n = 61
cells), P < 0.004). (g) White blood cell counts (WBC) in recipient mice administered
doxycycline for the indicated lengths of time. Each point represents one mouse; the line
indicates the mean WBC of the cohort. (h) Analysis of relative engraftment in peripheral
blood after competitive transplants in which MSI2-transgenic (M), or control rtTA (C), bone
marrow (CD45.2+) was mixed with competitor wild-type marrow (CD45.1+) at the indicated
ratios. (i) Percentage CD45.2+ cells in the long-term HSC (LSK CD34−), LSK and LK cell
compartments in the bone marrow of mice transplanted with a 3:1 ratio of MSI2- or rtTA-
expressing (CD45.2+) cells to wild-type cells (CD45.1+) at 20 weeks after
transplantation, +P < 0.05, **P < 0.001.
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Figure 3.
Ectopic MSI2 cooperates with BCR-ABL1 in promoting leukemia progression. (a)
Immunoblot of BaF3 cells transduced with control vector MSCV-IRES-EGFP (MIG) or
vector carrying MSI2 (M). (b) Numbers of EGFP+ BaF3 cells remaining 4 d after cytokine
withdrawal. Representative of five independent experiments from two independent clones,
details in Supplementary Methods. (c–f) Analysis of disease parameters including spleen
and liver weight (c), white blood cell count (d) and bone marrow and spleen cellularity (e,f)
in diseased mice killed at 14 d (representative of ten mice per group and two independent
assays). (g) Flow cytometric analysis of spleen cells from leukemic mice, stained for Mac1
and Gr1 and gated on BCR-ABL1+GFP+ cells. Average percentages for the diseased cohort
are indicated near gates for Mac1highGr1high and Mac1highGr1low populations, +P < 0.05,
**P < 0.001. Supplementary Figure 10c contains statistical analyses. (h) H&E staining of
bone marrow (BM) and spleen (SP) from diseased mice. Scale bars, 250 μm.
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Figure 4.
Increased MSI2 expression in human myeloid leukemias is associated with aggressive
disease and immature phenotype. (a) Immunoblot analysis in human AML cell lines, normal
human bone marrow cell and granulocytes. The MSI2 doublet indicates two alternative
isoforms from the MSI2 gene. (b) Cell proliferation in the indicated cell lines after infection
with lentivirus expressing control or MSI2-specific shRNAs. Error bars indicate s.e.m. from
at least five independent experiments per cell line scramble control (red) and two different
shRNAs (blue). (c,d) Apoptosis and differentiation based on annexin staining and CD16,
CD11b staining. A representative flow cytometric plot is shown in Supplementary Figure
11d; error bars represent s.e.m. from at least three independent experiments. +P < 0.05, *P <
0.01, **P < 0.001. (e) Analysis of Oncomine gene expression data with increased MSI2
expression in myeloid blast crisis (n = 33) versus chronic phase (n = 57, P < 0.001)24,30,
accelerated phase (n = 9) and lymphoid leukemia (B-ALL; n = 6). (f) Survival analysis in
human subjects (n = 436) of the Bullinger data set stratified by MSI2 expression. MSI2 high
and low expression is detailed in the Supplementary Methods, (median survival, 693 d
versus 238 d; P = 0.0004. (g) Survival analysis in human subjects (n = 163), in the Metzeler
data set for the cohort of CN-AML divided by MSI2 expression27. (h) Unsupervised
clustering of the MSI2 shRNA gene signature in the human subjects from the Bullinger data
set in f. Gene expression patterns of the subjects with the positive cluster represents subjects
that fit with the MSI2–knocked-down gene signature, whereas the negative cluster represents
subjects that cluster into a separate group from the shRNA gene signature. Subjects with
MSI2-high expression in red and MSI2-low expression in green are plotted above the
clustering based on f. The FLT3 internal tandem mutation is indicated by blue lines, and
NPM1 status is indicated with black lines. (i) Overall survival plot of positive correlation
and negative correlation clusters from the MSI2 shRNA gene expression signature in h. P <
0.004.
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